598 related articles for article (PubMed ID: 8423765)
1. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
[TBL] [Abstract][Full Text] [Related]
2. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
Gallagher EP; Wienkers LC; Stapleton PL; Kunze KL; Eaton DL
Cancer Res; 1994 Jan; 54(1):101-8. PubMed ID: 8261428
[TBL] [Abstract][Full Text] [Related]
3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
5. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
[TBL] [Abstract][Full Text] [Related]
6. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
7. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
9. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
Desta Z; Soukhova N; Mahal SK; Flockhart DA
Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
[TBL] [Abstract][Full Text] [Related]
10. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.
Postlind H; DanielsonA ; Lindgren A; Andersson SH
Drug Metab Dispos; 1998 Apr; 26(4):289-93. PubMed ID: 9531513
[TBL] [Abstract][Full Text] [Related]
11. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
Kroemer HK; Fischer C; Meese CO; Eichelbaum M
Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
[TBL] [Abstract][Full Text] [Related]
12. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
13. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.
Ekström G; Gunnarsson UB
Drug Metab Dispos; 1996 Sep; 24(9):955-61. PubMed ID: 8886604
[TBL] [Abstract][Full Text] [Related]
14. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
15. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450.
Hashizume T; Mise M; Terauchi Y; O L; Fujii T; Miyazaki H; Inaba T
Drug Metab Dispos; 1998 Jun; 26(6):566-71. PubMed ID: 9616193
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
Pearce RE; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 2001 Dec; 29(12):1548-54. PubMed ID: 11717173
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.
Desta Z; Soukhova N; Morocho AM; Flockhart DA
J Pharmacol Exp Ther; 2001 Aug; 298(2):508-20. PubMed ID: 11454912
[TBL] [Abstract][Full Text] [Related]
18. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes.
Abass K; Reponen P; Turpeinen M; Jalonen J; Pelkonen O
Drug Metab Dispos; 2007 Sep; 35(9):1634-41. PubMed ID: 17576805
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone.
Kroemer HK; Mikus G; Kronbach T; Meyer UA; Eichelbaum M
Clin Pharmacol Ther; 1989 Jan; 45(1):28-33. PubMed ID: 2910635
[TBL] [Abstract][Full Text] [Related]
20. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
